Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. - sprookjes - yvandenbroek - TriplyDB

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.

http://www.wikidata.org/entity/Q35598464

about

Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Considerations for a Pediatric Biopharmaceutics Classification System (BCS): application to five drugs.Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology Population pharmacokinetic analysis of voriconazole and anidulafungin in adult patients with invasive aspergillosis.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Advances in treating acute myeloid leukemia.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults.Integrated population pharmacokinetic analysis of voriconazole in children, adolescents, and adults.Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Safety, Efficacy, and Exposure-Response of Voriconazole in Pediatric Patients With Invasive Aspergillosis, Invasive Candidiasis or Esophageal Candidiasis.Invasive candidiasis and candidaemia in neonates and children: update on current guidelines.Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Pharmacokinetic considerations in treating invasive pediatric fungal infections.Pharmacodynamic studies of voriconazole: informing the clinical management of invasive fungal infections.Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre.Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.The Clinical Significance of Voriconazole Therapeutic Drug Monitoring in Children With Invasive Fungal Infections.Voriconazole and the liver.Pediatric Invasive Aspergillosis.Severe neurological disorders and refractory aspergillosis in an adolescent treated by vincristine and voriconazole.A Physiologically Based Pharmacokinetic Model for Voriconazole Disposition Predicts Intestinal First-pass Metabolism in Children

P2860

Q27025299-91BD4914-44ED-4B80-927D-69EA75D90D7D Q33681237-F8A6BF18-7702-48DC-A553-2D8FCC5BFC6F Q33827819-141C61B6-81D3-4230-8F88-464272FBB2AF Q34058346-746390C4-816B-44B8-B092-E864B134E102 Q34138276-80EE5FA3-3A05-4076-A99F-B8E411CDE6DC Q34312351-00CAA60B-C23A-45E1-B3AD-7B39F510BB34 Q34505582-5E51F7E3-71F8-41FC-9687-D6F218AF954D Q34596313-A4077B21-AA51-4D28-8306-4491FC4D52FC Q35105949-2C41C89D-E5AC-498A-8679-9D285B8D189E Q35598532-CEB5357F-1083-428B-8737-BD4DC387CC7B Q36018595-62D68E06-06BE-4BF4-932F-80746C8C0A8C Q36927577-BE8B9594-D7D8-43BB-9D52-719A8B908A94 Q36948094-F1BB9E71-BC86-476D-AC17-0358CDED207A Q37688257-8A767EDE-08B4-48F3-9F19-72648A9999B0 Q37693296-8C166CE0-E15A-48CA-B618-ED3CD59111F3 Q38263282-447E4806-82CC-4829-A6A7-30A70205E427 Q38526795-C92AA5DA-FC8F-4B27-9FA0-355A7847D928 Q38775809-320BDDBC-D474-47D3-9A21-41E156A76FD4 Q38816614-733A232C-4992-4046-A670-0A48CF2E0BFB Q38880522-1F1CD32B-C2F9-4EE0-A0A9-FCDA51E785EA Q39196770-CFB3134E-EFC8-4A8F-8D4B-5DD502A2D3C4 Q39797076-F1D89422-B7D0-4C66-B9A3-ECD204DC61BE Q39893350-353D5406-4684-4287-B19A-99B3738D07AF Q40290020-CA32514C-999E-439A-BC9A-C9178029D8D4 Q40913870-20BC32E0-51E0-41FD-87DE-553D9D4F47C9 Q42027433-48B47AC6-FF78-409E-833A-FF9B99AE0568 Q49612998-AC0C06D8-50DC-4F98-9F37-3CA5DE8885FA Q53117928-969EDEE9-C1FA-4E62-AFB0-B60776B31F07 Q57730442-2FE9A742-E47D-43FD-9876-70579294F198

P2860

Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults.

http://www.wikidata.org/entity/Q35598464

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Comparison of pharmacokinetics ...... d children and healthy adults.

@ast

Comparison of pharmacokinetics ...... d children and healthy adults.

@en

type

label

Comparison of pharmacokinetics ...... d children and healthy adults.

@ast

Comparison of pharmacokinetics ...... d children and healthy adults.

@en

prefLabel

Comparison of pharmacokinetics ...... d children and healthy adults.

@ast

Comparison of pharmacokinetics ...... d children and healthy adults.

@en

P1433

Q35598464-91D8F939-EBC1-4DFD-9123-9484B7E8BF2E

P1476

Q35598464-C27F8D74-0BEA-476C-928A-2BB12A81318E

P2093

Q35598464-0C471AB5-BE3C-40C5-9081-FB8A625D6330

Q35598464-2C94ADC0-405B-4BDA-A6C5-C23235D29809

Q35598464-571B209B-2CE6-421D-8F7F-74829EFE11C1

Q35598464-7D8470C6-298C-4EA9-A8E5-467D17E77FEA

Q35598464-9509C24F-BA3C-40D0-9639-7158B2745534

Q35598464-996224E4-DAB3-4FD6-824B-BE56C355252E

Q35598464-ADCC5C5D-70B1-4EDF-9A40-C435F60B68B9

Q35598464-B7DBBA6F-75A6-4B8D-97DF-977774F5DD77

Q35598464-B9C539B9-4BC9-47CC-8CA0-F6F0E993D2B6

Q35598464-C7A87E70-47D8-460A-BE99-F35F98A24C9D

P2860

Q35598464-31790E92-C7BF-4370-9E25-66641B10D82A

Q35598464-329A55E1-E7E4-4D29-BF65-34C2011719C1

Q35598464-3C6E2E7F-5939-4640-969E-E95E253D92F3

Q35598464-622C0E06-B1C2-475C-9A48-A9E4B7BB1DE1

Q35598464-75991461-14C7-419C-937C-04DFFD4F8BBE

Q35598464-87DA8014-2A6B-4D16-9983-2F9CE00A510D

Q35598464-911D6B05-B4C1-481B-B869-21FBEAB87412

Q35598464-965C7EE1-0510-44A7-9E9A-769268EBF5EC

Q35598464-96CA2F0F-C3A4-4819-8B2F-A45F57025282

Q35598464-9B68DD60-2833-46AB-B1A4-C5F1178CD0F4

P304

Q35598464-D2B41FA8-5AC7-4B5D-9E69-CA04FD860A24

P31

Q35598464-E2B24305-CE90-438C-8417-BD49E8A56A57

P356

Q35598464-FAEF471E-0B44-48E7-9B06-5746B9AE4421

P407

Q35598464-24C19DCB-0B2D-4682-9D3F-F807BA7CFEB5

P433

Q35598464-79CA7B52-8CEB-401A-8CC6-8E7BD4C7848C

P478

Q35598464-20750C5B-1166-4DC4-8CC8-9603BE1E97AD

P577

Q35598464-02B6BAD2-731C-4381-A21B-C64ADA1CDE05

P698

Q35598464-65787470-38DE-489F-A016-B5C71ABE5DC9

P932

Q35598464-9D8F81B4-CC83-43DF-B7F3-C19AAF9C4893

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Comparison of pharmacokinetics ...... d children and healthy adults.

@en

P2093

Alice Baruch

http://www.w3.org/2001/XMLSchema#string

Antonio Arrieta

http://www.w3.org/2001/XMLSchema#string

Eneida Nemecek

http://www.w3.org/2001/XMLSchema#string

Haydar Frangoul

http://www.w3.org/2001/XMLSchema#string

Jeffrey Blumer

http://www.w3.org/2001/XMLSchema#string

Lolie C Yu

http://www.w3.org/2001/XMLSchema#string

Michael L Graham

http://www.w3.org/2001/XMLSchema#string

Ping Liu

http://www.w3.org/2001/XMLSchema#string

Robert A Krance

http://www.w3.org/2001/XMLSchema#string

Scott M Bradfield

http://www.w3.org/2001/XMLSchema#string

P2860

Voriconazole therapeutic drug monitoring.

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens.

Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.

Voriconazole pharmacokinetics and pharmacodynamics in children.

Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients.

Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.

Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.

In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature.

Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects.

P304

5770-5779

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00531-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21968355

http://www.w3.org/2001/XMLSchema#string

P932

3232783

http://www.w3.org/2001/XMLSchema#string